Active-ingredient Dossier
Letrozole
Active-ingredient Dossier for Letrozole (aromatase inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: FEMARA
- Brand: ARX-LETROZOLE
- Brand: FEMOLET
- Brand: GYNOTRIL
- Brand: LETROZOLE
- Brand: LETROZOLE
- Therapeutic area: Oncology
What is
Letrozole Letrozole is an aromatase inhibitor.
Australian brands containing
Letrozole — FEMARA — ARX-LETROZOLE — FEMOLET — GYNOTRIL — LETROZOLE — LETROZOLE-WGR — ACCOZOLE — APO-LETROZOLE — DILETOZOL
Therapeutic areas
Letrozole is registered in oncology, with 11 brands containing the ingredient.
Sponsor landscape
Letrozole is marketed by eight sponsors: Cipla, Strides Pharma Science, Accord Healthcare, Arrotex Pharmaceuticals, Novartis Pharmaceuticals, and Alphapharm.
PBS and regulatory activity
One brand containing letrozole has a PBS-listed item, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome on record is 1 March 2022, with one brand holding a PBAC outcome. No AusPARs have been recorded for letrozole.